Original ResearchPublished 8 October 2026Pathogen spectrum and triple-criteria interpretation algorithm of BALF-targeted NGS in children with refractory severe community-acquired pneumonia in mountainous Northeastern Sichuan: a single-center retrospective studyRongjie Chen · Zhe Xu · Tingting He · Xiao Liu · Yi Ding · Xin HouFrontiers in Cellular and Infection Microbiologydoi 10.3389/fcimb.2026.1929990
ReviewPublished 22 September 2026Molecular systems of emerging viruses: replication, host immune evasion, cross-species adaptation and precision countermeasuresAbdul Bari Hejran · Parwiz Niazi · Mohammad Yaqoub SanginFrontiers in Virologydoi 10.3389/fviro.2026.1926007
Original ResearchPublished 18 August 2026Adverse drug events in hospitalized COVID-19 patients: a pharmacovigilance perspective on ICU management and fentanyl exposureMichele Ferreira Murgel · Marcel de Souza Borges Quintana · Roberta Olmo Pinheiro · Vítor Santos da Silva · Cláudia Luciana dos Santos Moura · Vanessa da Gama Oliveira · Cláudia Maria Valete Rosalino · Gilberto Marcelo Sperandio da SilvaFrontiers in Epidemiologydoi 10.3389/fepid.2026.1770145
ReviewPublished 30 July 2026Beyond one drug–one target: AI-guided discovery of multi-target antiviral therapeuticsVrinda Gupta · Sahil Sharma · Vikrant Abbot · Rohit Bhatia · Neeraj Choudhary · Dinesh KumarFrontiers in Virologydoi 10.3389/fviro.2026.1853552
Original ResearchPublished 29 May 2026High-throughput repurposing screen identifies a DHODH inhibitor as a potent antiviral candidate against chikungunya virusEliana Castro · Diego Ezequiel AlvarezFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1846068
RNA ResearchPublished 6 September 2023RNA damage: the forgotten target of clinical compoundsNicole Simms · John R. P. KnightFrontiers in RNA Researchdoi 10.3389/frnar.2023.1248236
